Overview

Webcast ImageWebcast
Q2 2017 Clovis Oncology, Inc. Earnings Conference Call (Replay)
08/02/17 at 4:30 p.m. ET
Q2 2017 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, August 2, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$71.61
Change (%) Stock is Down 0.49 (0.68%)
Intraday High$72.72
Intraday Low$71.01
Volume583,321
Data as of 08/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
08/02/17Clovis Oncology Announces Second Quarter 2017 Operating Results
Strong second quarter of launch for Rubraca® (rucaparib) in U.S. with $14.6M reported in net sales Positive topline data from the ARIEL3 study reported on June 19, 2017; presentation of full dataset confirmed at European Society for Medical Oncology 2017 Congress in Madrid Clovis plans to submit a supplemental New Drug Application (sNDA) for a second-line and later maintenance treatment indication before ... 
Printer Friendly VersionDownload PDF
07/31/17Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo® (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types
Pivotal Phase 3 Trials Planned for 2017 will Evaluate Rubraca in Combination with Opdivo, Rubraca as Monotherapy, and Opdivo as Monotherapy in First Line Maintenance Treatment for Advanced Ovarian and Advanced Triple-Negative Breast CancersPhase 2 Trial will Evaluate Opdivo in Combination with Rubraca and Other Compounds in Metastatic Castration-Resistant Prostate Cancer (NEW YORK and BOULDER, CO, July 31, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) and Clovis Oncology, Inc. (Nasda... 
Printer Friendly VersionDownload PDF
07/19/17Clovis Oncology to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 2
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 19, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.